Research Article

Interleukin-6 Promotes Epithelial-Mesenchymal Transition and Cell Invasion through Integrin β6 Upregulation in Colorectal Cancer

Qi Sun,1 Yukui Shang,2 Fengkai Sun,3 Xiwen Dong,4 Jun Niu,5 and Fanni Li6

1Department of General Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
2Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China
3Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China
4Department of Experimental Hematology, Beijing Institute of Radiation Medicine, Beijing 100850, China
5Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, China
6Department of Talent Highland, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China

Correspondence should be addressed to Fanni Li; fannycpu@163.com

Received 2 June 2020; Revised 5 July 2020; Accepted 20 July 2020; Published 13 August 2020

Academic Editor: Antonio Desmond McCarthy

Copyright © 2020 Qi Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The metastatic potential of colorectal cancer (CRC) is intensively promoted by the tumor microenvironment (TME) in a paracrine manner. As a pleiotropic inflammatory cytokine, Interleukin-6 (IL-6) is produced and involved in CRC, the same scenario where integrin αvβ6 also becomes upregulated. However, the relationship between IL-6 and integrin αvβ6 as well as their involvement in the crosstalk between CRC and TME remains largely unclear. In the present study, we demonstrated a positive correlation between the expression of IL-6 and integrin β6 in CRC samples. The mutually promotive interaction between CRC and TME was further determined by an indirect coculture system. CRC cells could augment the secretion of IL-6 from fibroblasts, which in return induced invasion and integrin β6 expression of CRC cells. Through the classic IL-6 receptor/STAT-3 signaling pathway, IL-6 mediated the upregulation of integrin β6, which was involved in the invasion and epithelial-mesenchymal transition of CRC cells induced by IL-6. Taken together, our results reveal a paracrine crosstalk between IL-6 signals originating from the TME and increased the integrin β6 level of CRC. IL-6 induces CRC invasion via upregulation of integrin β6 through the IL-6 receptor/STAT-3 signaling pathway. Combined inhibition of IL-6 along with integrin β6-targeted strategy may indicate new directions for antitumor strategies for CRC.

1. Introduction

Due to environmental causes and risk factors in modern society such as intestinal pathogens and inflammation, colorectal cancer (CRC) is among the most common malignancies [1]. Distant metastasis remains one of the leading contributors of CRC-related deaths, despite recent advancements in surgery techniques and adjuvant therapy. Therefore, a better understanding is urgently needed to investigate the mechanism of CRC metastasis so as to further improve the clinical outcomes.

Even though many vital molecular mechanisms have been revealed involved in cancer progression, it seems not realistic to prevent CRC metastasis by targeting one oncogene or signaling pathway within cancer cells [2]. The tumor consists of malignant cancer cells and stromal cells that constitute the tumor microenvironment (TME). More and more studies have discovered that the metastatic potential of cancer cells not only depends on certain oncogenes and signaling pathways but also is intensively promoted by the TME in a paracrine manner [3]. The stromal cells in the TME can be activated by cancer cells but meanwhile pro-
Interleukin-6 (IL-6), a pleiotropic inflammatory cytokine which plays a vital role in immune and inflammatory response, is well considered as a key growth factor for malignancy. IL-6 can be produced by multiple cell types located within the TME, including tumor-infiltrating immune cells, stromal cells, and cancer cells themselves [5]. During classic signaling, IL-6 binds to IL-6 receptor (IL-6R), forming the heterohexameric complex followed by recruitment of cellular proteins and subsequent activation of signaling pathways including JAK/STAT-3, PI3K, and MAPK [6]. IL-6 has been shown to increase metastatic capability in a variety of tumor models by multiple mechanisms. IL-6 promotes cancer stemness and oncogenicity of osteosarcoma cells by upregulating a secreted phosphorylated glycoprotein osteopontin [7]. In addition to tumorigenesis, IL-6 contributes to chemoresistance and recurrence [8]. Moreover, IL-6 can serve as a prognostic indicator of poor survival [9, 10] as well as a predictor of therapeutic response [11, 12] in a wide range of tumors.

The best described mechanism under which IL-6 increases tumor invasion is by conferring tumor cells on an EMT phenotype, through which tumor cells transit from adherent epithelial to mobile mesenchymal states thus facilitating invasion and metastasis [13]. During the complex process of metastasis, integrins, a large family of cellular adhesion receptors, are involved in almost every step by mediating the adhesion and interaction of the invading cancer cells with surrounding cells and extracellular matrix (ECM) [14]. So far, 24 different subtypes of integrins, composed of α and β subunits, have been identified [13]. Integrin αvβ6 is the only subtype the β6 subunit could constitute, which is specifically expressed in the epithelia. Integrin αvβ6 is barely expressed in adult normal tissues but becomes substantially upregulated in the context of inflammation and malignancy, acting as an indicator of tumor progression [15]. Our previous researches have defined the important participation of integrin αvβ6 in cancer invasion, matrix metalloproteinase (MMP) secretion, and chemoresistance [16–18]. In addition, integrin αvβ6 plays a bidirectional regulation role between CRC cells and stromal cells [19].

Previous studies have reported that IL-6 associates with CRC progression. IL-6 is not only related to advanced tumor stages and poor survival of CRC patients [20] but also promotes the motility of CRC cells [21]. IL-6 is produced and involved in inflammation and carcinogenesis, the same scenario where integrin αvβ6 also becomes upregulated. A correlation of expression of IL-6 with integrin αvβ6 was recently reported [22]; however, many questions still remain as to whether the expression of integrin αvβ6 is mediated by the activation of the IL-6 signaling pathway rather than being a concomitant phenomenon, since IL-6 may directly induce EMT of cancer cells to promote metastasis. Furthermore, the downstream mechanism of IL-6-induced invasion as well as the relationship between IL-6 and integrin αvβ6 remains largely unknown. In this study, we analyzed the effect of IL-6 on the expression of integrin αvβ6 and further characterized the roles of IL-6 and integrin αvβ6 in the paracrine crosstalk between the TME and CRC cells.

2. Materials and Methods

2.1. Cell Culture and Transfection. CRC cell lines HT-29 and Colo205 and fibroblast cell line CCD-18Co from the colon were purchased from ATCC. Human normal colon mucosal epithelial cell line NCM460 was obtained from INCELL. HT-29 and Colo205 were cultured in complete Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), with essential supplementation including penicillin/streptomycin solution, while NCM460 was cultured in complete RPMI-1640 medium. CCD-18Co was cultured in ATCC-formulated Eagle’s Minimum Essential Medium (#30-2003) with 10% FBS. All the cells were incubated at 37°C in a 5% CO₂ humidity atmosphere. The recombinant human IL-6 was purchased from R&D Systems. For the function blocking, the specific antibody 10D5 against integrin β6 was purchased from Merck Millipore and neutralizing anti-IL-6 as well as anti-IL-6R from R&D Systems. To knock down integrin β6 (#144659), IL-6R (#106147), or STAT-3 (#116558), cells were transfected with specific siRNA (Thermo Fisher Scientific) using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions. For the inhibition of the STAT-3 pathway, specific STAT-3 inhibitors Stattic and Cryptotanshinone (CTS), ERK/MAPK inhibitor U0126, and PI3K inhibitor LY294002 were purchased from SelleckChem.

2.2. Primary CRC Samples. For the immunohistochemistry (IHC) assay, a total of 155 CRC patients with intact clinical information who underwent radical operation were selected between May 2015 and June 2017 from the First Affiliated Hospital of Xi’an Jiaotong University. All the samples were histopathologically confirmed by two pathologists independently. Written informed consents were obtained from all patients. The protocol was approved by the Institutional Medical Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University.

2.3. IHC. IHC staining was performed on formalin-fixed paraffin-embedded CRC slide sections. Optimal antigen retrieval was induced in citrate buffer at pH 6.0 and 95°C for 30 min. The sections were blocked with 10% normal goat serum, followed by incubation with primary antibody against IL-6 (#6672, Abcam) or integrin β6 (Clone 442.5C4, Millipore Sigma) overnight at 4°C before incubation with secondary antibody conjugated with HRP. Finally, the staining was established by a DAB peroxidase substrate (Beyotime). The extent and intensity of IHC staining for IL-6 and integrin β6 were scored by two blinded observers under a light microscope. Briefly, the intensity of staining was graded as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong) and the extent of staining as 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%), or 4 (76-100%). The product of intensity and extent was used as the final IHC score. The patients were further classified into low or high expression group based on IL-6 immunostaining with the median IHC score as the cut-off value.
2.4. Coculture Assay. The indirect coculture of CRC cells with fibroblasts was established using Transwell membranes (0.4 μm pore size, Merck Millipore) for the paracrine cross-talk study. CCD-18Co cells (5.0 × 10⁵ cells) were seeded on the bottom of a 24-well culture plate with 500 μl fibroblast culture medium. In addition, HT-29 or Colo205 cells (1.0 × 10⁵) were seeded onto Transwell inserts with 100 μl DMEM. After 12 h, the Transwell inserts with cancer cells were transferred to the culture plate containing fibroblasts and cocultured for 72 h. As a blank control (monoculture), fibroblast culture medium without CCD-18Co in the plate or DMEM without cancer cells in the Transwell inserts was prepared.

2.5. Enzyme-Linked Immunosorbent Assay (ELISA). The culture medium was collected after coculture for 72 h and centrifuged to detect the concentration of supernatant IL-6 using the human IL-6 ELISA kit (Boster) according to the manufacturer’s instructions.

2.6. Quantitative PCR (qPCR). Total RNA of cells was harvested using the TRIzol reagent, and cDNA was synthesized following the manufacturer’s protocol (TaKaRa). qPCR was performed on a LightCycler 480 system (Roche Life Science). For the calculation of the fold change of the mRNA levels, the 2⁻ΔΔCq method was used with the human housekeeper gene GAPDH as the internal reference. The primers of human integrin β6 were forward 5′-TCCATCTGGAGTGGGC GAAAG-3′ and reverse 5′-CTGTCGGCTACACTGAG AG-3′. The primers of human integrin αv were forward 5′-GGCTGCATATTTCGGATTCTG-3′ and reverse 5′-CCATTCAGCTTGTGTCGCTGG-3′. The primers of human GAPDH were forward 5′-CTGGGCTACACTGA GCACC-3′ and reverse 5′-AAGTGGTGCTGAGGCCA TG-3′.

2.7. Western Blotting. The protein lysates were harvested using RIPA lysis buffer, with quantification performed using the Pierce BCA kit (Thermo Fisher Scientific). For immunoblot analysis, 25-50 μg protein was boiled in Laemmli buffer and loaded on an 8-10% denaturing SDS-polyacrylamide gel and then transferred to PVDF membranes, which were blocked with 5% bovine serum albumin before immunoblotting with primary antibodies against IL-6R (#167742, Abcam), integrin β6 (Clone 442.5C4, Millipore Sigma), phospho-STAT-3 (#9145), total STAT-3 (#4904), phospho-ERK1/2 (#9106), phospho-AKT (#4060), Vimentin (#5741), E-cadherin (#3195) (Cell Signaling Technology), αv (sc-9969), and β-actin (sc-47778) (Santa Cruz). After the incubation with secondary antibodies, the bands were detected by enhanced chemiluminescence.

2.8. Transwell Invasion Assay. The invasion capability of cells was assessed using Transwell Boyden chambers (Corning, 8 μm pore size) precoated with Matrigel. After treatment with the indicated reagent or siRNA, 1.0 × 10⁵ CRC cells in serum-free medium were seeded on the upper chamber, with medium containing indicated doses of IL-6 in the lower chamber for 24 h. For the coculture Transwell invasion assay, fibroblasts (1.0 × 10⁵) were seeded to the lower chamber in 600 μl culture medium, and CRC cells (1.0 × 10⁵) were seeded on the upper chamber in 100 μl serum-free DMEM with a coculture interval of 24 h. The monoculture system without fibroblasts was used as the control. After the removal of the cells on the upper side of the membrane, the cells on the lower surface were fixed, stained, and counted in four random fields (magnification, ×400).

2.9. Statistics. Statistical analyses were performed using GraphPad Prism 5 software. Data were presented as means ± SEM. Student’s t-tests were performed for the comparison of two means while ANOVA for 3 or more data sets. The association between IHC staining of IL-6 and integrin β6 was determined by the Mann-Whitney test. Chi-squared tests were used to explore the association of IL-6 and integrin β6 expression with different clinicopathological variables. p < 0.05 was considered to be statistically significant.

3. Results

3.1. There Is a Positive Correlation between the Expression of IL-6 and Integrin β6 in CRC Samples. IHC analysis demonstrated that the immunostaining of IL-6 was detected predominantly in the cytoplasm of tumor as well as stromal cells (Figures 1(a) and 1(b)) while the staining of integrin β6 in the cytoplasm and membrane of tumor cells (Figures 1(c) and 1(d)). Among the 155 CRC samples, 76 cases (49%) showed high IL-6 expression and 61 cases (39%) showed positive expression of integrin β6. To further investigate whether there was a correlation between IL-6 and β6 expression, the samples were divided into high and low expression groups based on IL-6 immunostaining, and the IHC scores of integrin β6 from two groups were compared by Mann-Whitney analysis, which indicated that the IL-6-high group demonstrated higher immunostaining of integrin β6 than the IL-6-low group (Figure 1(e)). Therefore, the expression of IL-6 was positively related to the expression of integrin β6 in CRC samples. The association of IL-6 and integrin β6 expression with clinicopathological factors is summarized in Table 1. Both IL-6 and integrin β6 expression were associated with poor tumor differentiation and advanced N stage and TNM stage. Moreover, IL-6 expression was also related to the tumor stage, while integrin β6 expression to M stage, indicating an association of IL-6 and integrin β6 expression with disease severity in the CRC patients.

3.2. IL-6 Induces Invasion of Human CRC Cells through IL-6R. IL-6 was previously shown to increase the motility of HCT-116 CRC cells [23]. Here, the effect of IL-6 was further verified on the invasion of two other CRC cell lines HT-29 and Colo205. The invasion capability of HT-29 and Colo205 cells could be increased by IL-6 in a dose-dependent manner (Figures 2(a) and 2(b)). Inhibition of IL-6R by neutralization antibody as well as siRNA targeting IL-6R could remarkably inhibit IL-6-mediated cell invasion (Figures 2(c) and 2(d)). These data indicated that IL-6 could promote invasion via IL-6R in CRC cells.
3.3. Upregulation of Integrin β6 Involves in IL-6-Induced Invasion of CRC Cells. Given the positive correlation of IL-6 with integrin β6 in CRC samples (Figure 1(e)), and the critical role of integrin β6 in CRC cell migration, we hypothesized that integrin β6 might participate in IL-6-induced invasion of CRC cells. Based on qPCR assays, we found that the gene expression of integrin β6 was upregulated by IL-6 in a dose-dependent manner, while integrin αv was not affected (Figures 3(a) and 3(b)). Consistently, the protein level of integrin β6 was also increased upon IL-6 stimulation, confirming that IL-6 could upregulate the expression of integrin β6 (Figures 3(c) and 3(d)). In fact, as short as 15 h treatment with exogenous IL-6 was sufficient to induce integrin β6 transcription, indicating a potential direct regulation of integrin β6 by IL-6 in CRC cells (Supplementary Fig. 1a, b).

In contrast, we were unable to detect the expression of integrin β6 in NCM460 cells in the absence or presence of exogenous IL-6 (data not shown). Furthermore, the role of integrin β6 in IL-6-mediated cell invasion was verified by loss-of-function study. Inhibition of integrin β6 with function blocking antibody 10D5 or siRNA could remarkably suppress IL-6-induced cell invasion (Figures 3(e) and 3(f)). In addition, inhibition of IL-6R reduced IL-6-upregulated transcription and translation levels of integrin β6 (Figures 3(g) and 3(h)). These results suggested the important participation of integrin β6 in IL-6/IL-6R-induced invasion of CRC cells.

3.4. Involvement of Integrin β6 in IL-6-Induced EMT. EMT is well known for its pathological role in tumor invasion and
metastasis, and IL-6 has been shown to induce EMT in a paracrine manner in a variety of types of carcinoma including bladder [24] and pancreatic cancers [25]. Here, we show that in addition to cell invasion, IL-6 could also promote EMT of CRC cells (Figures 4(a) and 4(b)). Since IL-6 could upregulate integrin \( \beta 6 \), the cytoplasmic domain of which is critical to EMT [26]. We therefore examined whether integrin \( \beta 6 \) was involved in IL-6-mediated EMT in CRC cells. Inhibition of integrin \( \beta 6 \) could inhibit the suppression of E-cadherin and the induction of Vimentin mediated by IL-6 in both HT-29 and Colo205 cells (Figures 4(a) and 4(b)), thus reversing IL-6-induced EMT.

3.5. STAT-3 Signaling Pathway Participates in IL-6-Mediated Cell Invasion and Integrin \( \beta 6 \) Upregulation. The STAT-3 signaling pathway plays a prominent role in diverse cellular behaviors mediated by IL-6, including tumor cell survival, invasion, and metastasis [27]. We therefore investigated whether the STAT-3 pathway was involved in IL-6-mediated cell invasion and upregulation of integrin \( \beta 6 \). Pretreatment of cells with STAT-3 inhibitors Stattic or CTS could reduce IL-6-mediated cell invasion (Figure 5(c)). Moreover, addition of Stattic could significantly reverse IL-6-induced expression of integrin \( \beta 6 \) (Figure 5(d)). Consistently, suppression of STAT-3 by siRNA could not only reduce the invasion capability but also inhibit the upregulated expression of integrin \( \beta 6 \) by stimulation of IL-6 in CRC cells (Figures 5(e) and 5(f)). In contrast, while IL-6 could also expectedly activate ERK/MAPK and PI3K pathways in HT-29 cells, ERK/MAPK inhibitor U0126 could only inhibit IL-6-induced expression of integrin \( \beta 6 \) in a small degree while PI3K inhibitor LY294002 had no effect (Supplementary Fig. 2a, b), indicating that MAPK and PI3K pathways were dispensable in IL-6-induced integrin \( \beta 6 \) upregulation. Collectively, these data indicated that the STAT-3 signaling pathway was involved in IL-6-induced invasion and expression of integrin \( \beta 6 \) in CRC cells.

3.6. Fibroblast-Derived IL-6 Promotes the Invasion and Upregulation of Integrin \( \beta 6 \) in CRC Cells. To further investigate the crosstalk between cancer cells and TME, the indirect coculture assay was utilized, which showed that both HT-29 and Colo205 cells increased IL-6 secretion from fibroblasts (Figures 6(a) and 6(b)), and the mRNA level of IL-6 was predominantly induced in fibroblasts rather than CRC cell lines (Figures 6(c) and 6(d)), confirming that CRC cells could augment the production of IL-6 from the fibroblasts.

### Table 1: Association of IL-6 and integrin \( \beta 6 \) expression with clinicopathological factors in CRC cases.

| Clinicopathological factors | n   | IL-6 expression | p    | Integrin \( \beta 6 \) expression | p  |
|----------------------------|-----|-----------------|------|-----------------------------------|----|
|                            |     | Low     | High |                                  |    |
| Gender                     |     |         |      |                                  |    |
| Male                       | 83  | 40      | 43   | 0.458                             | 0.660 |
| Female                     | 72  | 39      | 33   |                                  |    |
| Age (years)                |     |         |      | 0.443                             | 0.746 |
| <60                        | 66  | 36      | 30   |                                  |    |
| ≥60                        | 89  | 43      | 46   |                                  |    |
| Differentiation            |     |         |      | 0.009                             | <0.001 |
| Well                       | 53  | 35      | 18   |                                  |    |
| Moderate                   | 59  | 29      | 30   |                                  |    |
| Poor                       | 43  | 15      | 28   |                                  |    |
| Tumor stage                |     |         |      | 0.013                             | 0.083 |
| T1-T2                      | 91  | 54      | 37   |                                  |    |
| T3-T4                      | 64  | 25      | 39   |                                  |    |
| N stage                    |     |         |      | <0.001                            | <0.001 |
| N0                         | 62  | 49      | 13   |                                  |    |
| N1                         | 58  | 21      | 37   |                                  |    |
| N2                         | 35  | 9       | 26   |                                  |    |
| M stage                    |     |         |      | 0.436                             | 0.006 |
| M0                         | 132 | 69      | 63   |                                  |    |
| M1                         | 23  | 10      | 13   |                                  |    |
| TNM stage                  |     |         |      | 0.029                             | 0.002 |
| I-II                       | 75  | 45      | 30   |                                  |    |
| III-IV                     | 80  | 34      | 46   |                                  |    |
Concomitantly, we also determined the effect of IL-6 secreted by fibroblasts on the expression of integrin β6 in CRC cells. The cancer cells in the coculture system demonstrated an upregulation of integrin β6, which could be antagonized via neutralizing antibody (Figures 6(e) and 6(f)). Moreover, both IL-6 antibody and integrin β6 antibody inhibited the enhanced CRC cell invasion when cocultured with fibroblasts, with the combination of both function blocking antibodies presenting the most significant inhibition (Figures 6(g) and 6(h)). In contrast, integrin β6 expression of NCM460 cells was undetectable under coculture with fibroblasts (data not shown). Taken together, these data confirmed the role of IL-6 from TME in the promotion of tumor invasion through upregulation of integrin β6 in CRC cells.

4. Discussion

The prognosis of CRC patients with recurrent or metastatic disease remains poor, as the treatment at later stages is always an obstacle. Since tumor progression is driven not only by dysregulation of genes in cancer cells but also by various kinds of stromal cells, it has become a research hotspot to consider the paracrine crosstalk between cancer cells and TME so as to develop novel treatment strategies combining anticancer and antistroma therapies [28].

Regarding the role of TME in a tumor, the major IL-6-producing cancer-associated fibroblasts (CAFs) promote cancer stemness and induce an immune adaptive inflammatory response, thus favoring CRC progression [29]. It is well known that CAFs facilitate malignancy by secreted factors and components of ECM. In accordance, our current study shows that IL-6 secretion from fibroblasts is much more abundant than that from CRC cells, but on the other hand, CRC cells augment IL-6 secretion from fibroblasts that in return facilitates the invasion of cancer cells, forming a positive mutual enhancement between CRC and TME. The bidirectional intercellular communications participate in response to environmental cues and are necessary in regard
to tumor development. Besides direct cell-cell contact, cancer cells can activate fibroblasts to initiate an inflammatory response, promoting the expression of IL-6 [30]. Multiple growth factors secreted by cancer cells, such as transforming growth factor-beta (TGF-β) [19] and platelet-derived growth factors [31], induce the transformation of fibroblasts. Furthermore, tumor-derived extracellular vesicles (EVs), including exosomes, are involved in tumor-fibroblast communication by transferring principal factors. EVs contain functional cellular components, such as proteins and microRNAs, which not only promote the differentiation of fibroblast into CAF but also induce chemokine secretion.

![Figure 3: Upregulation of integrin β6 is critical to IL-6/IL-6R-induced invasion of CRC cells.](image)

(a) qPCR analysis of integrin αv or β6 gene in HT-29 (a) and Colo205 (b) cells treated with IL-6 with various doses for 24 h. (c, d) Immunoblots showing the effect of IL-6 at indicated doses on the expression of integrin αv or β6 in HT-29 (c) and Colo205 (d) cells for 24 h. (e, f) Transwell invasion assays to assess the role of integrin β6 in IL-6-induced invasion. CRC cells were pretreated with antibody 10D5 for 1 h and maintained thereafter to block the function of integrin β6 or with siRNA for 24 h to knock down β6, followed by stimulation with 20 ng/ml IL-6 for 24 h. (g, h) The role of IL-6R in IL-6-mediated upregulation of integrin β6 was validated by qPCR (g) and western blotting (h) analyses. CRC cells were pretreated with function blocking antibody against IL-6R or siRNA targeting IL-6R to inhibit IL-6R, followed by stimulation with 20 ng/ml IL-6 for 24 h. Data represent the means ± SEM. n = 3 independent experiments. *p < 0.05 versus no IL-6 treatment control. #p < 0.05 versus IL-6-treated group. (a, b, e, g) Data shown is representative of 3 independent experiments.
from fibroblasts in both proximal surrounding and distal sites [32]. In addition, tumor-derived exosomal effects in fibroblasts are also influenced by the aggressiveness of cancer cells. The molecules encapsulated in EVs derived from cancer cells with high-metastatic property contribute to an appropriate TME creation for tumor metastasis [33]. Further investigations are still needed to uncover the specific mechanisms of CRC cells to promote IL-6 secretion from fibroblasts. In addition to fibroblast-derived IL-6, we verify that exogenous IL-6 induces CRC cell invasion via IL-6R, consistent with previous study that anti-IL-6R antibody suppresses exogenous IL-6 induces CRC cell invasion via IL-6R, consistent with previous study that anti-IL-6R antibody suppresses exogenous IL-6-induced invasion and integrin β6 expression.

As an indicator of aggressiveness, integrin β6 promotes EMT [35] and metastasis of CRC cells to the liver [36]. For the underlying mechanism, our study shows that IL-6/IL-6R induces the mRNA and protein levels of integrin β6 in a concentration-dependent manner. Besides, IL-6 is sufficient to induce integrin β6 transcription in a short time frame of stimulation, indicating the existence of a direct regulation. What is more important, integrin β6 is critical to IL-6-induced EMT and aggressiveness as inhibition of integrin β6 by function blocking antibody or siRNA could reverse the facilitation of invasion mediated by IL-6 in CRC cells. In contrast, we were unable to detect integrin β6 in normal colon epithelial cells. This is consistent with the fact that integrin β6 is barely expressed in normal epithelia but becomes significantly upregulated, acting as a tumor promoter, in the context of malignancy. Liang et al. [22] showed that IL-6 and integrin β6 expression could be used as a predictor of poor overall survival of CRC; here, we not only validate the positive relationship between the expression of IL-6 and integrin β6 besides their association with disease severity of CRC patients in another single-center study but also show for the first time that IL-6 upregulates integrin β6 expression. In addition to classic signaling, transsignaling also plays an important role in the TME to recruit tumor-associated stromal cells [37]; therefore, further study is needed to investigate whether the IL-6 transsignaling pathway is involved in the process here. It should be noted that antagonizing IL-6 by neutralizing antibody in the coculture system partially inhibits invasion and integrin β6 expression of CRC cells, indicating that TME may secrete other growth factors to nourish and enhance CRC aggressiveness [38]. In fact, in regard to the crosstalk of integrin β6 with paracrine signals, the SDF-1/CXCR4 axis is able to induce directional migration and liver metastasis of CRC cells by upregulating integrin αvβ6 [39]. On the other hand, integrin αvβ6 of CRC cells activates fibroblasts via TGF-β signaling followed by increased production of SDF-1 from CAFs [19]. One important characteristic of IL-6 is the persistent activation in the whole process of inflammatory bowel disease and CRC, while the upregulations of other cytokines like TGF-β1, IL-10, and IL-23 only show up primarily during CRC development [38]. Therefore, even though the interaction between cancer cells and TME is dynamic and complicated, we speculate that IL-6 already starts to play an important role during the early stages of inflammatory bowel disease and CRC, thus sustaining CRC progression all the time till the rise of other paracrine signals as well as integrin pathways. Most anticancer therapies are currently developed to specifically target cancer cells, but the tumor stroma can promote the resistance of cancer cells to such therapies, eventually leading to fatal recurrence and metastasis. Our work now moves forward a further step in this complex crosstalk between CRC cells and TME, showing the mutually promotive roles of IL-6 and integrin β6 in CRC progression.

The discovery of TME-derived IL-6-mediated signaling pathways is helpful for further understanding the mechanism underlying CRC metastasis, which may contribute to the development of therapeutic strategies. Among the signaling pathways, STAT-3 is the main transactivator downstream of IL-6 signaling, and IL-6 is involved in the activation of oncogenic STAT-3 in many kinds of cancer [40]. Therefore, we investigated whether IL-6-induced upregulation of integrin β6 is mediated by STAT-3 signaling. IL-6 stimulation leads to phosphorylation of STAT-3 (Tyr 705), and inhibition of STAT-3 by specific inhibitors or siRNA abrogates IL-6-induced invasion and integrin β6 upregulation, indicating the participation of this classical signaling cascade in response to IL-6. Aberrant activities of STAT-3 contribute
to malignancy and thus are a potential therapeutic target for CRC. It should be noted that in our experiments, exogenous IL-6 activates STAT-3 transiently as the phosphorylated level of STAT-3 reached the peak within 30 min upon exogenous IL-6 stimulation, probably due to suppressor of cytokine signaling 3 (SOCS3). The activation of IL-6 signaling cascade can induce SOCS3 expression, which forms a negative feedback loop to terminate the STAT-3 signaling pathway in turn, leading to a basal state for the cells. Both epigenetic suppression of SOCS3 [41] and the paracrine signals in the TME [42] may contribute to the sustaining stimulus for STAT-3 activation in multiple forms of cancer. Nevertheless, the

![Image](https://via.placeholder.com/150)

**Figure 5:** STAT-3 pathway is involved in IL-6-mediated cell invasion and upregulation of integrin β6. (a, b) Immunoblots showing the effect of IL-6 (20 ng/ml) with indicated treatment intervals on the expression of phospho-STAT-3 (Tyr705) (p-STAT-3) and total-STAT-3 (t-STAT-3) in HT-29 (a) and Colo205 (b) cells. (c, e) Transwell invasion assay showing the role of the STAT-3 pathway in IL-6-induced invasion. HT-29 and Colo205 cells were pretreated with STAT-3 specific inhibitor Stattic or CTS (5 μM) (c) for 1 h or with siRNA (e) for 24 h to knock down STAT-3, followed by stimulation with IL-6 (20 ng/ml) for 24 h. Data represent the means ± SEM. *p < 0.05 versus no IL-6 treatment control. **p < 0.05 versus IL-6-treated group. (d, f) Immunoblots showing the role of the STAT-3 pathway in IL-6-mediated upregulation of integrin β6. HT-29 and Colo205 cells were pretreated with STAT-3 specific inhibitor Stattic (5 μM) (d) or siRNA (f) before the treatment with IL-6 (20 ng/ml) for 24 h, and the expression of integrin β6 was detected. (a, b, d, f) Data shown is representative of 3 independent experiments.
Figure 6: Fibroblast-derived IL-6 promotes the invasion and integrin β6 upregulation in CRC cells. (a, b) ELISA assay shows IL-6 secretion from the coculture system. HT-29 (a) and Colo205 (b) cells increased the production of IL-6 from CCD-18Co cells. \( n = 3 \) independent experiments. * \( p < 0.05 \) versus monoculture control. (c, d) qPCR analysis of integrin β6 gene in HT-29 (c) and Colo205 (d) cells as well as CCD-18Co cells under coculture compared to monoculture. Data represent the means ± SEM. \( n = 3 \) independent experiments. ** \( p < 0.01 \) versus CCD-18Co in monoculture control. (e, f) Immunoblots showing the role of IL-6 from the coculture system in the upregulation of integrin β6 in CRC cells. The protein level of integrin β6 in HT-29 (e) and Colo205 (f) cells was increased after coculture with CCD-18Co cells and antagonized by neutralizing antibody against IL-6. Data shown is representative of 3 independent experiments. (g, h) Transwell invasion assay showing the role of IL-6 and integrin β6 in the enhanced invasion by coculture of CRC cells with CCD-18Co cells. Both function blocking antibodies against IL-6 and integrin β6 partially suppressed the coculture system-mediated invasion of HT-29 (g) and Colo205 (h) cells, and combined inhibition demonstrated the most significant abrogation. \( n = 3 \) independent experiments. * \( p < 0.05 \) versus monoculture control. \# \( p < 0.05 \) versus no antibody treatment coculture group.
transient STAT-3 activation here is still efficient to induce integrin β6 upregulation in CRC cells. The combination of STAT-3 and integrin β6 expression has been reported to have a better prognostic performance than either alone in gallbladder carcinoma [43]. STAT-3 has been shown to be involved in promoting integrin β6 transcription in oral squamous cell carcinoma [44] and prostate cancer cells [45]. Moreover, Niu et al. [46] recently characterized the region located at the core promoter of integrin β6 and demonstrated the binding sites for transcription factor STAT-3. The present study now shows that STAT-3 is a critical transcription factor involved in IL-6-induced upregulation of integrin β6 in CRC cells. In our prior study, we found that the MAP-K/Ets-1 signaling pathway was also involved in the dysregulation of integrin β6 [47]; however, through pathway inhibitors, we found that ERK/MAPK and PI3K pathways were dispensable in IL-6-induced integrin β6 expression, suggesting the preferred role of the STAT-3 pathway in IL-6-mediated CRC progression. Our future work will further characterize the mechanisms of the crosstalk between CRC and TME so as to provide valuable candidates for preventing or treating CRC progression.

5. Conclusions

In summary, our results reveal a novel link between paracrine signals originating from TME and increased integrin β6 level of CRC. We for the first time discover that integrin β6 becomes upregulated upon IL-6 stimulation through the IL-6R/STAT-3 pathway, and integrin β6 plays a vital role in IL-6-induced EMT and invasion of CRC cells. These findings have potential therapeutic implications for targeted therapy. Since integrin β6 participates in the paracrine crosstalk between the TME and CRC cells, combined inhibition of IL-6 signaling along with integrin β6-targeted strategies may indicate new directions for antitumor strategies for CRC.

Abbreviations

CRC: Colorectal cancer
TME: Tumor microenvironment
EMT: Epithelial-mesenchymal transition
IL-6: Interleukin-6
IL-6R: IL-6 receptor
ECM: Extracellular matrix
MMP: Matrix metalloproteinase
CAF: Cancer-associated fibroblast
IHC: Immunohistochemistry
ELISA: Enzyme-linked immunosorbent assay
TGF-β: Transforming growth factor-beta
EVs: Extracellular vesicles
SOCS3: Suppressor of cytokine signaling 3.

Data Availability

The raw data related to this paper may be requested from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

Authors’ Contributions

Conceptualization was handled by QS and FL. Methodology and investigation were made by QS and YS (in vitro) and FS and XD (IHC). Analysis and interpretation of data were conducted by FS, YS, and XD. Writing and review revision of the manuscript were managed by QS, JN, and FL. Study supervision was done by JN and FL. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81702362 and 81803026), China Postdoctoral Science Foundation (2019T120922 and 2018M631176), Key Research and Development Program of Shaanxi (No. 2019KW-067), Shaanxi Province Postdoctoral Science Foundation (2018BSHYDZZ49), and Natural Science Foundation of Shandong Province of China (ZR2017BH072 and ZR2017BH095).

Supplementary Materials

Supplementary Fig. 1: effect of IL-6 on the transcription of integrin β6 of CRC cells. qPCR analysis of integrin β6 gene in HT-29 (a) and Colo205 (b) cells treated with IL-6 (20 ng/ml) for different period intervals. Data represent the means ± SEM. n = 3 independent experiments. *p < 0.05 versus no IL-6 treatment control. Supplementary Fig. 2: ERK/MAPK and PI3K pathways are dispensable in IL-6-induced integrin β6 expression. HT-29 cells were pretreated with ERK/MAPK inhibitor U0126 (20 μM) (a) or PI3K inhibitor LY294002 (20 μM) (b) for 1 h before the treatment with IL-6 (20 ng/ml) for 24 h, and the expression of integrin β6 was detected. Data shown is representative of 3 independent experiments. (Supplementary Materials)

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] J. Plava, M. Cihova, M. Burikova, M. Matuskova, L. Kucrova, and S. Miklikova, “Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer,” Molecular Cancer, vol. 18, no. 1, p. 67, 2019.
[3] B. Ren, M. Cui, G. Yang et al., “Tumor microenvironment participates in metastasis of pancreatic cancer,” Molecular Cancer, vol. 17, no. 1, p. 108, 2018.
[4] X. Qin, M. Yan, X. Wang et al., “Cancer-associated fibroblast-derived IL-6 promotes head and neck cancer progression via the osteopontin-NF-kappa B signaling pathway,” Theranostics, vol. 8, no. 4, pp. 921–940, 2018.
[5] J. Mauer, J. L. Denson, and J. C. Bruning, “Versatile functions for IL-6 in metabolism and cancer,” Trends in Immunology, vol. 36, no. 2, pp. 92–101, 2015.

[6] Y. Guo, F. Xu, T. Lu, Z. Duan, and Z. Zhang, “Interleukin-6 signaling pathway in targeted therapy for cancer,” Cancer Treatment Reviews, vol. 38, no. 7, pp. 904–910, 2012.

[7] C. Zhang, K. Ma, and W. Y. Li, “Expression of interleukin-6 and integrin αvβ6 in colon cancer: association with clinical outcomes and prognostic implications,” Cancer Investigation, vol. 37, no. 3, pp. 174–184, 2019.

[8] J. T. Lin, J. Y. Wang, M. K. Chen et al., “Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6,” Experimental Cell Research, vol. 319, no. 14, pp. 2216–2229, 2013.

[9] C. Anderberg, J. Y. Wang, M. K. Chen et al., “The assessment of the prognostic value of interleukin 6 subunit regulates epithelial-to-mesenchymal transition,” Anticancer Research, vol. 34, no. 2, pp. 659–664, 2014.

[10] C. Cooper and F. G. Giancotti, “Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance,” Cancer Cell, vol. 35, no. 3, pp. 347–367, 2019.

[11] L. Koivisto, J. Bi, L. Hakkinen, and H. Larjava, “Integrin αvβ6: structure, function and role in health and disease,” The International Journal of Biochemistry & Cell Biology, vol. 99, pp. 186–196, 2018.

[12] J. Wang, J. Wu, J. Hong et al., “PKC promotes the migration of colon cancer cells by regulating the internalization and recycling of integrin αvβ6,” Cancer Letters, vol. 311, no. 1, pp. 38–47, 2011.

[13] H. Gao, C. Peng, B. Liang et al., “β6 integrin induces the expression of metalloproteinase-9 and metalloproteinase-9-9 in colon cancer cells via ERK-ETS1 pathway,” Cancer Letters, vol. 354, no. 2, pp. 427–437, 2014.

[14] S. Liu, J. Wang, W. Niu et al., “The β6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer,” Cancer Letters, vol. 328, no. 2, pp. 325–334, 2013.

[15] C. Peng, X. Zou, W. Xia et al., “Integrin αvβ6 plays a bidirectional role between colon cancer cells and cancer-associated fibroblasts,” Bioscience Reports, vol. 38, no. 6, 2018.

[16] C. Heichert, K. Scheibe, A. Schmied et al., “STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis,” Gut, vol. 69, no. 7, pp. 1269–1282, 2020.

[17] K. Rasanen, E. Lehtinen, K. Nokelainen et al., “Interleukin-6 increases expression of serine protease inhibitor Kazal type 1 through STAT3 in colorectal adenocarcinoma,” Molecular Carcinogenesis, vol. 55, no. 12, pp. 2010–2023, 2016.

[18] B. Liang, L. Li, R. Miao et al., “Expression of interleukin-6 and integrin αvβ6 in colon cancer: association with clinical outcomes and prognostic implications,” Cancer Investigation, vol. 37, no. 3, pp. 174–184, 2019.

[19] J. T. Lin, J. Y. Wang, M. K. Chen et al., “Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6,” Experimental Cell Research, vol. 319, no. 14, pp. 2216–2229, 2013.

[20] C. R. Goulet, A. Champagne, G. Bernard et al., “Colon-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling,” BMC Cancer, vol. 19, no. 1, p. 137, 2019.

[21] W. Li, L. Sun, J. Lei, Z. Wu, Q. Ma, and Z. Wang, “Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor-stromal crosstalk under hypoxic conditions via the IL-6/ERK/NF-kB axis,” Oncology Reports, vol. 44, no. 1, pp. 382–392, 2020.

[22] C. Lee, C. Lee, S. Lee, A. Siu, and D. M. Ramos, “The cytoplasmic extension of the integrin β6 subunit regulates epithelial-to-mesenchymal transition,” Anticancer Research, vol. 34, no. 2, pp. 659–664, 2014.

[23] D. E. Johnson, R. A. O’Keefe, and J. R. Grandis, “Targeting the IL-6/JAK/STAT3 signalling axis in cancer,” Nature Reviews Clinical Oncology, vol. 15, no. 4, pp. 234–248, 2018.

[24] K. C. Valkenburg, A. E. de Groot, and K. J. Pienta, “Targeting the tumour stroma to improve cancer therapy,” Nature Reviews Clinical Oncology, vol. 15, no. 6, pp. 366–381, 2018.

[25] P. T. Huynh, E. J. Beswick, Y. A. Coronado et al., “CD90(+) stromal cells are the major source of IL-6, which supports cancer stem-like cells and inflammation in colorectal cancer,” International Journal of Cancer, vol. 138, no. 8, pp. 1971–1981, 2016.

[26] H. J. Hugo, S. Lebret, E. Tomaskovic-Crook et al., “Contributions of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment,” Cancer Microenvironment: official journal of the International Cancer Microenvironment Society, vol. 5, no. 1, pp. 83–93, 2012.

[27] C. Anderberg, H. Li, L. Fredriksson et al., “Paracrine signaling by platelet-derived growth factor-CC promotes tumour growth by recruitment of cancer-associated fibroblasts,” Cancer Research, vol. 69, no. 1, pp. 369–378, 2009.

[28] Y. Naito, Y. Yamamoto, N. Sakamoto et al., “Cancer extracellular vesicles contribute to stromal heterogeneity by inducing chemokines in cancer-associated fibroblasts,” Oncogene, vol. 38, no. 28, pp. 5566–5579, 2019.

[29] N. Tominaga, N. Kosaka, M. Ono et al., “Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier,” Nature Communications, vol. 6, no. 1, pp. 6716, 2015.

[30] T. Nagasaki, M. Hara, H. Nakanishi, H. Takahashi, M. Sato, and H. Takeyama, “Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction,” British Journal of Cancer, vol. 110, no. 2, pp. 469–478, 2014.
[35] R. C. Bates, D. I. Bellovin, C. Brown et al., “Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma,” The Journal of Clinical Investigation, vol. 115, no. 2, pp. 339–347, 2005.

[36] G. Y. Yang, K. S. Xu, Z. Q. Pan et al., “Integrin alphavbeta6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver,” Cancer Science, vol. 99, no. 5, pp. 879–887, 2008.

[37] I. L. Campbell, M. Erta, S. L. Lim et al., “Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain,” The Journal of Neuroscience: the official journal of the Society for Neuroscience, vol. 34, no. 7, pp. 2503–2513, 2014.

[38] T. V. Velikova, L. Miteva, N. Stanilov, Z. Spassova, and S. A. Stanilova, “Interleukin-6 compared to the other Th17/Treg related cytokines in inflammatory bowel disease and colorectal cancer,” World Journal of Gastroenterology, vol. 26, no. 16, pp. 1912–1925, 2020.

[39] B. Wang, W. Wang, W. Niu et al., “SDF-1/CXCR4 axis promotes directional migration of colorectal cancer cells through upregulation of integrin avβ6,” Carcinogenesis, vol. 35, no. 2, pp. 282–291, 2014.

[40] H. Kitamura, Y. Ohno, Y. Toyoshima et al., “Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy,” Cancer Science, vol. 108, no. 10, pp. 1947–1952, 2017.

[41] L. Huang, B. Hu, J. Ni et al., “Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis,” Journal of Experimental & Clinical Cancer Research, vol. 35, no. 1, p. 27, 2016.

[42] F. M. Corvinus, C. Orth, R. Moriggl et al., “Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth,” Neoplasia, vol. 7, no. 6, pp. 545–555, 2005.

[43] L. Enyu, W. Na, Z. Chuanzong et al., “The clinical significance and underlying correlation of pStat-3 and integrin avβ6 expression in gallbladder cancer,” Oncotarget, vol. 8, no. 12, pp. 19467–19477, 2017.

[44] M. Xu, X. Chen, H. Yin et al., “Cloning and characterization of the human integrin β6 gene promoter,” PLoS One, vol. 10, no. 3, article e0121439, 2015.

[45] J. Azare, K. Leslie, H. Al-Ahmadie et al., “Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6,” Molecular and Cellular Biology, vol. 27, no. 12, pp. 4444–4453, 2007.

[46] W. Niu, Q. Y. Bo, J. Niu et al., “Identification of integrin β6 gene promoter and analysis of its transcription regulation in colon cancer cells,” World Journal of Gastrointestinal Oncology, vol. 12, no. 5, pp. 526–534, 2020.

[47] Q. Sun, F. Sun, B. Wang et al., “Interleukin-8 promotes cell migration through integrin avβ6 upregulation in colorectal cancer,” Cancer Letters, vol. 354, no. 2, pp. 245–253, 2014.